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AbstrAct
Osmotic demyelination syndrome is a rare complication following treatment of chronic hyponatraemia. We des-
cribe a case of a middle-aged man known with hypertension and hypothyroidism who presented with a reduced 
level of consciousness and a generalised convulsion. Laboratory results revealed severe hyponatraemia and 
hypokalaemia. Following rapid overcorrection of the serum sodium concentration, his level of consciousness 
remained unchanged, and he developed quadriplegia. Magnetic resonance imaging of the brain revealed central 
pontine myelinolysis (CPM). The patient died 3 weeks after hospitalisation. Other than rapid overcorrection of 
chronic hyponatraemia, this case also highlights the important role of potassium in the pathogenesis of CPM. 
Therefore, when severe chronic hyponatraemia is accompanied by hypokalaemia, the latter should be corrected 
first to further reduce the risk of CPM.
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INtrODUctION
Osmotic demyelination syndrome (ODS) was first 
described in 1959 [1]. The term encompasses central 
pontine myelinolysis (CPM) and extrapontine myelinolysis. 
The most common risk for ODS is rapid overcorrection 
of chronic hyponatraemia, especially when the serum 
sodium concentration is <120 mmol/L [2]. Additional 
high-risk comorbidities include chronic alcoholism, malnu-
trition, advanced liver disease, diuretic use, hypokalaemia 
and hypophosphataemia [2,3]. There is a wide range of 
clinical features, including confusion and drowsiness, 
dysphagia, dysarthria, varying degrees of quadriplegia and 
coma or locked-in syndrome [4]. We describe a case of 
a middle-aged man who was found to have severe, symp-
tomatic hyponatraemia and, following rapid over-
correction, developed CPM. 
cAsE PrEsENtAtION 
A 50-year-old man known with hypothyroidism was 
diagnosed with hypertension and was initiated on 
indapamide and perindopril. According to his wife, he 
was otherwise in good health and was of sober habits.
Three months later, he became confused and was taken 
to another hospital by a co-worker. It was noted that 
his confusion was preceded by five days of severe 
headaches, nausea, diarrhoea and malaise. During hospi-
talisation, he had a generalised convulsion, which was 
aborted with intravenous clonazepam. Clinical examina-
tion revealed a reduced level of consciousness with a 
Glasgow Coma Scale of 5/15. His blood pressure was 
141/107 mmHg, he was afebrile and his oxygen satura-
tion was 90% on ambient air. Hydration was thought 
to be normal. Crackles and bronchial breath sounds 
were audible in the lower lung zones. The rest of the 
clinical examination was unremarkable. A chest radio-
graph revealed symmetrical mid and lower lung zone 
patchy infiltrates and a computed tomogram (CT) of 
the chest revealed bilateral lobar consolidation. Labo-
ratory results on admission revealed a sodium concen-
tration of 114 mmol/L (normal range: 136–145 mmol/L); 
potassium concentration of 2.2 mmol/L (normal range: 
3.5–5.1 mmol/L) and a capillary glucose concentration of 
170
14.1 mmol/L. See Table 1. The patient was administered 
supplemental oxygen at 3 L per minute and oxygen sat-
uration improved to 100%. Owing to his low level of 
consciousness and convulsions, acute hyponatraemia was 
considered. The patient was treated with two ampoules 
of 10% sodium chloride solution intravenously. The fol-
lowing day the sodium concentration was 126 mmol/L; 
however, his level of consciousness remained unchanged. 
As a result, a contrasted CT of the brain was performed, 
which was reported to be normal. Polymerase chain 
reaction for SARS-CoV-2 was positive. 
Fifteen days following hospitalisation, the patient was trans-
ferred to our hospital. On arrival, he was drowsy but 
responded to a pain stimulus, pupils were equal and reac-
tive to light, he had a gaze preference to the right, tone 
was reduced in the lower limbs but was normal in the 
upper limbs, reflexes were brisk with the exception of 
reduced ankle jerks, and testing of power was limited but 
he was not moving all limbs symmetrically. Magnetic 
resonance imaging was performed 30 days after his initial 
presentation and revealed features consistent with CPM. 
See Figure 1. The patient remained comatose and required 
a tracheostomy. He died 3 weeks after admission at our 
hospital.
DIscUssION  
Our discussion focuses on the evolution of our patient’s 
hyponatraemia and risk factors leading to CPM. He was 
recently prescribed indapamide for hypertension, which 
caused chronic hyponatraemia. Indapamide, a thiazide-like 
diuretic, has been reported to cause severe hyponatraemia 
and mild hypokalaemia [5]. Mechanisms responsible for 
thiazide-associated hyponatraemia include impaired free 
water clearance due to poor distal nephron solute delivery 
and hypovolaemia-induced antidiuretic hormone (ADH) 
secretion [5]. A meta-analysis reported that thiazide-asso-
ciated hyponatraemia typically developed in elderly women 
(age >75 years) with a normal body mass index [6]. The 
mean time to its development was 19 days; however, it 
may occur months later, as was found in our case.
Hypothyroidism has been linked to the development of 
hyponatraemia, especially during myxoedema coma [7]. 
Mechanisms include a reduced cardiac output, which trig-
gers baroreceptors leading to the release of ADH, poor 
water delivery to the diluting segments of the nephron and 
poor solute intake [7]. Our patient’s thyroid function tests 
at hospital admission indicated poor control, possibly 
exacerbating his chronic hyponatraemia.
The syndrome of inappropriate ADH secretion induced by 
the pneumonia was another likely contributor [8]. Our 
patient also had a history of diarrhoea. The latter caused 
hypovolaemia, further stimulating both ADH release as 
well as thirst. Continued water intake along with an inability 
of the kidneys to excrete a water load likely caused an 
acute component of the chronic hyponatraemia. 
CPM occurred in our patient for the following reasons. 
Although the initial concern was that he may have had 
acute, severe hyponatraemia and thus cerebral oedema, 
the overzealous correction of the serum sodium concen-
tration to nearly normal using hypertonic saline was a 
major factor. Clinically, it may be very diff icult to decide 
whether hyponatraemia is only acute or acute-on-chronic. 
For this reason, it may be more prudent to raise the 
serum sodium concentration by an amount that is safe 
while simultaneously reducing intracranial pressure, usually 
~4–6 mmol/L [2]. Our patient’s serum sodium concentra-
tion was increased by 12 mmol/L within 24 hours. During 
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Sodium (mmol/L) 136–145 114 126
Potassium (mmol/L) 3.5–5.1 2.2 2.4
Urea (mmol/L) 2.5–6.4 8.6 2.7
Creatinine (µmol/L) 62–124 198 96
TSH (mIU/L) 0.27–4.20 32.24 –
T4 (pmol/L) 2.0–22.0 7.8 –
Abbreviations: TSH, thyroid stimulating hormone; T4, thyroxine.
Figure 1.  t2-weighted magnetic resonance imaging (sagittal 
view), indicating central pontine myelinolysis (yellow arrow).
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chronic hyponatraemia, the recommended increase in 
serum sodium concentration should not exceed 8 mmol/L 
per day [2]. The reason for this is to allow neurons to 
import osmoles. In response to changes in serum osmo-
lality, neurons have the unique ability to adapt by export-
ing osmoles when cells are swollen [9]. These osmoles 
consist of electrolytes, predominantly potassium, the major 
intracellular cation, which move rapidly, and organic 
osmoles, which move more slowly. This adaptation takes 
about 48 hours [2]. Once serum sodium begins to return 
to normal, neurons must reimport osmoles [2]. Since 
potassium constitutes most of the imported electrolyte 
osmoles, patients with hypokalaemia are at high risk of 
ODS [10]. Autopsy or MRI-confirmed cases of ODS were 
found in patients with simultaneous hypokalaemia and 
hyponatraemia in which the sodium concentration was 
corrected by more than 10 mmol/L within 24 hours [2]. 
Central pontine myelinolysis has also been reported in a 
patient with isolated hypokalaemia [11]. Therefore, since 
potassium plays a pivotal role in ODS [10], overlooking 
even relatively mild hypokalaemia may have devastating 
consequences if it is not addressed during the manage-
ment of chronic, severe hyponatraemia. 
The mechanism by which hypokalaemia predisposes to 
ODS remains unknown. It is speculated that there is an 
inability of brain vascular endothelial cells and/or glial cells 
to regulate their volume when hyponatraemia is accom-
panied by hypokalaemia [10]. The sodium/potassium-
ATPase (Na/K-ATPase) located in the cell membrane is 
important for the regulation of cell volume. Cellular 
expression of this pump in glial and endothelial cells of 
the brain may be reduced in the presence of hypokalaemia, 
as has been demonstrated in skeletal muscle [12]. There-
fore, during rapid increases in serum osmolality, these cells 
cannot rapidly adapt because of the low potassium avail-
ability as well as a lack of Na/K-ATPase pumps. It has been 
recommended that correction of hypokalaemia should be 
attained prior to correcting the hyponatraemia to reduce 
the risk of ODS [10]. 
Recently, it has been reported that hypokalaemia is a com-
mon finding in patients with COVID-19 infection [13]. 
SARS-CoV-2 gains entry to its host by binding to the 
angiotensin-converting enzyme 2 (ACE2) receptor and 
reduces ACE2 expression. This causes increased angiotensin 
II concentrations, resulting in secondary hyperaldostero-
nism with subsequent renal potassium wasting and ulti-
mately hypokalaemia [13]. A recent study reported that 95 
of 175 patients (55%) admitted with COVID-19 had 
hypokalaemia at the time of hospitalisation [13]. They also 
found that renal potassium excretion was higher in patients 
with hypokalaemia, indicating renal potassium wasting. Our 
patient’s hypokalaemia was likely due to multiple mecha-
nisms that included diarrhoea, renal losses due to thiazide-
like diuretic use as well as the effect of COVID-19 on renal 
potassium homeostasis.
cONcLUsIONs
Other than rapid overcorrection of chronic hyponatraemia, 
this case also highlights the important role of potassium in 
the pathogenesis of CPM. Therefore, when severe chronic 
hyponatraemia is accompanied by hypokalaemia, the latter 
should be corrected first to further reduce the risk of CPM. 
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